A Rheumatoid Arthritis Study in Participants

Summary

The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic drug (DMARD) therapy. This study is comprised of 2 periods: Period 1 - 24-week blinded treatment Period 2 - 48-week post-treatment follow-up

Timeline

Start

2011-01

Primary completion

2012-12

Completion

2013-07

Drugs

Indications